Member Info for AquaeSulis01

Just a little reminder re the "Golden Egg", Imutex products, and what we can expect following any announcement of an agreed sale'

IQ-AI pushed out a similar intent to sell their "non-core" product last Dec 19; impatient shareholders, me included, gave up on the sale ever happening. Following a just released RNS, the IQ-AI is up 80% as I type.

IQ-AI Ltd

("IQ-AI" or the "Company")

StoneChecker™ Update





In December 2019, IQ-AI made the strategic decision to focus existing resources and expand upon the Company's leading position in the neuro imaging field. This decision, aimed to align resources on projects that maximise value for shareholders and overall Company value, launched a search for a buyer or partner for StoneChecker Software Limited.



Designed to analyse computed tomography (CT) datasets, StoneChecker evaluates the likelihood that kidney stones will break up during Extracorporeal Shock Wave Lithotripsy (ESWL), or "lithotripsy", procedure. Using shock waves to break up kidney stones into smaller pieces allows them to be easily passed thorough the body via the urinary tract. It is estimated, however, that lithotripsy procedures fail 29% of the time. Thus, the additional information provided by StoneChecker helps reduce the failed lithotripsy procedures performed on patients. In December 2018, StoneChecker was declared CE marked for European distribution. Then, on September 26, 2019, USA FDA 510(k) market clearance was obtained followed by Korean FDA (KFDA) market clearance earlier this year.



IQ-AI has now signed a Letter of Intent (LOI) with a major international medical group wishing to buy Stonechecker and due diligence has commenced. The transaction, if completed, will comprise cash consideration plus ongoing royalty on sales. Further information will be released as events progress.

Well any new partners will no doubt be looking to buy into Ceres so keep those shares tight to your chest for now
From the last Trading Update:
Outlook
· Expect to sign new customer partnerships in the second half of the year as commercial demand remains strong

The current share price is more than supported with hatched chickens (existing combined pipeline of near term target contracts for hVIVO and Vennc. £110m), only need one of the remaining chickens to hatch (Substantial new pipeline of opportunities to develop Covid challenges studies £35m-£70m, Third party pharma Covid laboratory testing opportunities
£5m-£10m Rollout of Covid antibody testing£10m-£30m with further upside potential) and then there is the golden egg, Imutex products, FLU-v, a phase III ready universal influenza vaccine candidate, AGS-v, a phase II ready mosquito saliva vaccine, zika, malaria, and dengue etc).

There are a queue of pharmas waiting for Orphan to conduct challenge studies, the green light will come once the attenuated version of Covid 19 (nasty bits taken out which removes the ethical concerns) is ready eta Autumn

I heard a rumour you were back in ADUK. Little song for you too. https://m.youtube.com/watch?v=-gWqrP30YXQ

Wouldn't disagree Thunder, but not necessarily to pre-Covid crisis levels is all I am saying because of the extra costs v average funeral revenue

Pleased for LTHs this is doing so well but to answer your question Thunder, perhaps this is why
https://www.expressandstar.com/news/uk-news/2020/07/29/cheaper-covid-19-funerals-hurt-dignitys-bottom-line/

Funeral services have been stripped back during the coronavirus crisis as big send-offs were banned to slow the spread of the disease, new data from funeral provider Dignity shows.
Dignity said that the proportion of “simple and limited service” funerals it performed tripled in April, May and June.
During the same months last year, only 13% of people chose one of the simple and limited funerals for their loved ones, while 53% picked Dignity’s more expensive “full service”.
However, that split was almost flipped in the second quarter of this year, as 37% of people chose the simple, and only 26% the full service, Dignity said on Wednesday.
It meant that despite a large rise in the number of funerals, with deaths up 47% to 207,000, Dignity’s profit took a hit.
The £58.3 million profit the funeral provider registered in the second quarter of 2019 was swapped for a £13.6 million loss this time around.
£13.6 million Dignity's loss in the second quarter of 2020
Dignity
The simpler funerals are much less expensive than the full service. Last year Dignity made almost £3,600 from each full service, but only £2,047 from the simpler plan.
It also made a lot less money on flowers and other ancillary items, £49 on average, compared to £233 this time last year.
More people died in the last quarter than at any point in the last two decades, Dignity said.
But the business did not capitalise on the increase, partly because of the simpler plans.
However, it also cost Dignity a lot more to run the services, as keeping up safety measures proved costly.
All the £5.5 million benefit Dignity got from business rates relief “and more” was used to buy personal protective equipment (PPE) to keep staff and clients safe, it said.
It also hinted that Covid-19 may hurt the business’s long-term prospects as the number of deaths might be lower in 2021 and 2022 than they were last year.

carvey,

Capacity is likely to be 60% not 50%

From cruise.co.uk
Some Experts are predicting sailing with around 60% maximum capacity, no self service buffets open, some social distancing measures.
More days at sea, a new standard of cleaning, perhaps crew members sleeping in inside cabins.
One thing is certain loyal cruise fans are still backing their favorites and are still booking a huge number of cruises.
This has been a really busy time for us taking bookings for 2021 & 2022.

Also, there is a steady switch to more local no fly deals which explains the booking increase for next year's trips. Some great deals out there so hardly surprising.

https://www.graphene-info.com/researchers-come-promising-new-design-graphene-enhanced-fuel-cells

Researchers come up with a promising new design for graphene-enhanced fuel cells
Researchers at University College London, Queen Mary University of London and Humboldt Universität zu Berlin have suggested a design for a hydrogen fuel cell, with graphene as a key component. The new research promises to address some of the roadblocks that have thus far hindered the development of this clean, non-toxic, renewable technology, thus opening up hydrogen fuel cells as a potential clean-energy breakthrough.

At the moment the US Department of Energy estimates that the cost of energy generated by hydrogen fuel cells is around $61 per kilowatt. The ultimate aim is to get this down to $30 per kilowatt. The scaling up in the production of graphene-coated nanoparticles suggested in the paper could help significantly in this quest. The team’s findings could also extend beyond the field of fuel cells, lending itself to some exciting technological applications.

Hydrogen fuel cells are a method of converting chemical energy to electrical energy with only one by-product?—?water. As such they are not just clean and renewable, but also non-toxic. Such fuel cells rely on what is known as a polymer electrolyte membrane (PEM) to function?—?a barrier that can simultaneously allow the conduction of protons, separate gases, and electrically insulates the fuel cell’s electrodes.

Of the materials suggested for the construction of such a membrane, referred to as an electrode support material, graphene leads the way. It ?is resistant to corrosion, highly conductive and possesses a large surface area. Factor into this, a high-resistance to acidic conditions and its incredibly light-weight nature and the graphene/ fuel cell combination seems like a perfect match.

But there are still major problems that stand in the way of the widespread adoption of graphene-based hydrogen fuel cell technology. Graphene-based electrodes can suffer from high-defect concentrations arising from a non-uniform coverage of nanoparticles, both of which can negatively impact performance. This problem only gets worse during the cell’s lifecycle and nanoparticles get stripped from the graphene.

The solution the team suggested involves the creation of platinum nanoparticles coated with layers of graphene. Such particles, according to the team, are of the optimal dimensions to be uniformly dispersed across a surface. In this way, they can be used to coat an electrode in such a way that efficiency drops are all but eliminated.

North, Cathal is on holiday in his native Ireland and has deliberately chosen a location without connectivity son that his children do not spend all the time on line. That said, he will no doubt of arranged a set time to contact the office each day for regular updates so that in the event of significant news, he can rubber stamp the release of a RNS.

Today's news perhaps?

https://www.newcivilengineer.com/latest/costain-kier-and-motts-win-thames-water-roles-28-07-2020/
Costain, Kier and Motts win Thames Water roles
28 JUL, 2020 BY CATHERINE KENNEDY

Costain, Kier and Mott MacDonald Bentley are among firms set to deliver construction work for Thames Water under the latest contracts awarded for AMP7/AMP8.

The water company has awarded a two-lot contract for its capital programmes for non-infrastructure and infrastructure projects.

Agree with your summary Genghis. One thing I would add re the 7z watercut at 53% now that it is being run under esp is that if Dr T was correct about perched water then we could in the very near future see that percentage rapidly falling

haggis, no problem with 12% being manageable if stable just your reference to the well being dry which was incorrect. The RNS is quite specific and yet people are ramping or deramping with their own facts and doubts. Colonel I suggest you learn to read as well, the RNS states quite explicitly 5000 bopd from 7z and 12000 bopd from 6

How can 6 well be described as dry when the watercut is now 12%?

DFLYNCH, the figures can be found by going through the RNS. For example kerogen ; 18th Apr 16 Hurricane Energy plc, the UK-based oil and gas company focused on hydrocarbon resources in naturally fractured basement reservoirs, is pleased to announce that it has conditionally raised gross proceeds of approximately £52.1 million through a proposed issue of 347,245,265 New Ordinary Shares at a price of 15 pence per share. The Company is pleased to have obtained the support of Kerogen Capital, an independent private equity fund manager specialising in the international oil and gas sector. Kerogen Investments No. 18 Limited, an entity which is part of the fund managed by Kerogen Capital, has conditionally subscribed for 293,911,931 of these New Ordinary Shares (the "Kerogen Subscription") to raise gross proceeds of approximately £44.1 million. 20th Oct 16 Hurricane Energy plc, the UK-based oil and gas company focused on hydrocarbon resources in naturally fractured basement reservoirs, is pleased to announce that it has conditionally raised gross proceeds of £70 million through a proposed issue of 205,882,353 Placing Shares at a price of 34 pence per share.The Company is grateful for the support of its existing shareholders, including Kerogen Investor and Crystal Amber who have conditionally subscribed for 93,017,647 of the Placing Shares to raise gross proceeds of £31.63 million. RN S 29th Jun 17 offer price 32p Kerogen Capital will subscribe for up to 85,309,258 Placing Shares in the Placing to raise gross proceeds of up to US$35 million.On 17 July 2019, Kerogen announced that it had sold 110 million ordinary shares in the Company at a price of 46.5 pence per share. Following settlement, which is expected to take place on 19 July 2019, Kerogen will hold approximately 16.0 per cent of the Company's issued ordinary share capital. This residual holding will be subject to a lock-up period of 120 days, subject to customary exceptions.



Hurricane notes that Kerogen has signalled its continued support for the Company as it continues to be a major shareholder with a 16.0 per cent interest and a nominated representative on Hurricane's board of directors. Kerogen has participated in each of the Company's significant placings since April 2016 and this transaction represents approximately a quarter of its current holding.

The catalyst will be the creation of an attenuated version of the virus, so that all these vaccines can be tested asap. This virus is too deadly to deliberately infect people with so let's hope the recent tie-up with CHIMagents pays dividends soon because at that point all the major pharmas will be forming an orderly queue

https://news.sky.com/story/coronavirus-warning-from-italy-effects-of-covid-19-could-be-worse-than-first-thought-12027348

No, rotten bunch in Nevada but plenty of gold

The target for producing an attenuated version of the Covid19 virus has always been the Autumn. To that end, the target has been de-risked by the option to acquire CHIMagents to assist with this task. So sit back and await the news that COVID 19 vaccine testing is scheduled to commence with the first three pharma x, y and z because when that RNS lands it will be too late to buy in at a bargain price. That's me back in the freezer for now as far as this share is concerned.

Well, I feel extremely fortunate to have had the opportunity to buy in here at 421.5 this morning. The placing resulted in an awful lot of shares being made available to the market so little wonder the share price which had been temporarily overheated immediately prior to the placing, has fallen back. As pointed out by others, the strong fundamentals of the company have not changed, a share certainly to invest in rather than trade at current prices

FF the US are busy looking after their own Graphene producers

https://www.graphene-info.com/nanograf-receives-165-million-us-department-defense-improve-batteries-power